@entity927 for preventing postpartum XXXX after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials.

@entity1 @entity398 @entity548 @entity190 @entity928 @entity1031 @entity927
INTRODUCTION: There are several published clinical trials of the use of @entity927 ( @entity928 ) in an obstetric setting, but no consensus on its use or guidelines for management. MATERIAL AND METHODS: The aim of this meta-analysis was to evaluate the effectiveness of @entity928 in reducing @entity190 when given prior to cesarean delivery. We performed a systematic search in electronic databases. We included all randomized controlled trials comparing the use of @entity928 prior to cesarean delivery with controls (either placebo or no treatment). RESULTS: Nine trials with 2365 @entity1 were included in the analysis. @entity1 who received @entity928 had significantly less postpartum @entity190 , a lower drop in hemoglobin and a lower incidence of postpartum @entity548 and severe postpartum @entity548 compared with controls. Moreover, the number of @entity1 who needed additional uterotonic agents was significantly lower in the @entity928 group than in controls. The percentage of @entity1 who required blood transfusions at, or immediately after, cesareans was significantly lower in the intervention group than in the controls. There was no difference in the incidence of @entity1031 events in the two groups. CONCLUSIONS: Prophylactic @entity928 given before cesarean skin incision in @entity1 undergoing cesarean delivery, under spinal or epidural anesthesia, significantly decreases @entity190 , including postpartum @entity548 and severe postpartum @entity548 , in addition to the standard prophylactic @entity398 given after delivery of the neonate. The effect of @entity928 on @entity1031 events and mortality as well as its use in high-risk @entity1 should be investigated further.
